Considerations and barriers to starting a new HAI pump program: an international survey of the HAI Consortium Research Network.
Journal
HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
31
05
2022
revised:
27
07
2022
accepted:
15
08
2022
pubmed:
10
9
2022
medline:
15
12
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
Widespread implementation of HAI pump chemotherapy has been limited by logistic and feasibility concerns. Recent studies demonstrating excellent outcomes have fueled renewed enthusiasm and multiple new programs have emerged. This survey aims to identify barriers critical to establish a successful HAI program. Using SurveyMonkey™, a 17-question survey assessing factors required for establishing a successful program was developed by 12 HAI Consortium Research Network (HCRN) surgical oncologists. Content analysis was used to code textual responses. Frequency of categories and average rank scores for each choice were calculated. Twenty-eight HCRN members responded to the survey. Implementation time varied, with 15 institutions requiring less than a year. Most programs (n = 17) became active in the past 5 years. Medical and surgical oncology were ranked most important for building a program (average ranking scores: 7.96 and 6.59/8). Administrative or regulatory approval was required at half of the institutions. The top 3 challenges faced when building a program were related to regulatory approval (6.65/9), device/equipment access (6.33/9), and drug (FUDR) access (6.25/9). Development of successful programs outside of historically established centers is feasible and requires a multidisciplinary team. Future collaborative efforts are critical for sustainability of safe/effective new programs.
Sections du résumé
BACKGROUND
Widespread implementation of HAI pump chemotherapy has been limited by logistic and feasibility concerns. Recent studies demonstrating excellent outcomes have fueled renewed enthusiasm and multiple new programs have emerged. This survey aims to identify barriers critical to establish a successful HAI program.
METHODS
Using SurveyMonkey™, a 17-question survey assessing factors required for establishing a successful program was developed by 12 HAI Consortium Research Network (HCRN) surgical oncologists. Content analysis was used to code textual responses. Frequency of categories and average rank scores for each choice were calculated.
RESULTS
Twenty-eight HCRN members responded to the survey. Implementation time varied, with 15 institutions requiring less than a year. Most programs (n = 17) became active in the past 5 years. Medical and surgical oncology were ranked most important for building a program (average ranking scores: 7.96 and 6.59/8). Administrative or regulatory approval was required at half of the institutions. The top 3 challenges faced when building a program were related to regulatory approval (6.65/9), device/equipment access (6.33/9), and drug (FUDR) access (6.25/9).
CONCLUSION
Development of successful programs outside of historically established centers is feasible and requires a multidisciplinary team. Future collaborative efforts are critical for sustainability of safe/effective new programs.
Identifiants
pubmed: 36085262
pii: S1365-182X(22)01553-2
doi: 10.1016/j.hpb.2022.08.008
pmc: PMC9771984
mid: NIHMS1836045
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2104-2111Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Références
Ann Surg Oncol. 2019 Dec;26(13):4599-4607
pubmed: 31641947
Ann Surg Oncol. 2022 Jan;29(1):35-36
pubmed: 34117578
BMC Cancer. 2019 Apr 5;19(1):327
pubmed: 30953467
Surg Forum. 1970;21:136-7
pubmed: 5514709
Ann Surg Oncol. 2017 Jan;24(1):150-158
pubmed: 27431415
J Am Coll Surg. 2019 Aug;229(2):217-219
pubmed: 30878584
Ann Surg. 1950 Oct;132(4):811-32
pubmed: 14771793
N Engl J Med. 2005 Feb 17;352(7):734-5
pubmed: 15716576
N Engl J Med. 1999 Dec 30;341(27):2039-48
pubmed: 10615075
J Clin Oncol. 2006 Mar 20;24(9):1395-403
pubmed: 16505413
Am J Med. 1950 Apr;8(4):535
pubmed: 15410760
Surg Gynecol Obstet. 1975 Aug;141(2):176-86
pubmed: 1154224
Clin Colorectal Cancer. 2012 Mar;11(1):53-9
pubmed: 21813336
J Am Coll Surg. 2021 Mar;232(3):332-338
pubmed: 33387624
Clin Colorectal Cancer. 2012 Mar;11(1):38-44
pubmed: 21803002
J Gastrointest Surg. 2022 Apr;26(4):764-771
pubmed: 34820727
Ann Surg Oncol. 2013 Sep;20(9):2901-7
pubmed: 23771246
Ann Surg Oncol. 2020 Dec;27(13):5086-5095
pubmed: 32779054
JAMA Oncol. 2020 Jan 01;6(1):60-67
pubmed: 31670750
J Clin Oncol. 2009 Jul 20;27(21):3465-71
pubmed: 19470932
J Surg Oncol. 2018 Dec;118(7):1065-1073
pubmed: 30376157
Ann Surg Oncol. 2014 Feb;21(2):501-6
pubmed: 24081807
Am J Pathol. 1954 Sep-Oct;30(5):969-77
pubmed: 13197542
J Am Coll Surg. 2005 Jul;201(1):57-65
pubmed: 15978444
Cancer Res. 1978 Nov;38(11 Pt 1):3784-92
pubmed: 151583
Oncology. 2011;80(3-4):153-9
pubmed: 21677464
J Surg Oncol. 2021 Jan;123(1):252-260
pubmed: 33095919
J Surg Oncol. 2018 Mar;117(4):634-643
pubmed: 29165816
J Clin Oncol. 2008 Dec 10;26(35):5721-7
pubmed: 19001325
J Clin Oncol. 2017 Jun 10;35(17):1938-1944
pubmed: 28426374
J Surg Oncol. 2016 Sep;114(3):342-7
pubmed: 27529576
Surg Gynecol Obstet. 1972 Jan;134(1):51-6
pubmed: 5007175